Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
e-STOP 2: Early Stop of Antibiotic Treatment in High-risk Febrile Neutropenic Paediatric Patients
NCT07590648Phase 4Not yet recruiting
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Jun 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in febrile neutropenia (FN) (2 arms), sponsored by Vall d'Hebron Research Institute. Primary endpoint: Composite rate of adverse outcomes attributable to invasive or clinically significant bacterial infection. Planned start Jun 2026; status: not yet recruiting.
02
Conditions
febrile neutropenia (FN)
Beyond the preview
Go deeper on NCT07590648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07590648.